CR20240342A - Vegf y proteína de fusión de unión a tie2 y sus usos descripción - Google Patents

Vegf y proteína de fusión de unión a tie2 y sus usos descripción

Info

Publication number
CR20240342A
CR20240342A CR20240342A CR20240342A CR20240342A CR 20240342 A CR20240342 A CR 20240342A CR 20240342 A CR20240342 A CR 20240342A CR 20240342 A CR20240342 A CR 20240342A CR 20240342 A CR20240342 A CR 20240342A
Authority
CR
Costa Rica
Prior art keywords
fusion protein
vegf
tie2
binding fusion
methods
Prior art date
Application number
CR20240342A
Other languages
English (en)
Spanish (es)
Inventor
Sangyeul Han
Philip Durost
Minkyung Choo
Kwangsoo Kim
Original Assignee
Ingenia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ingenia Therapeutics Inc filed Critical Ingenia Therapeutics Inc
Publication of CR20240342A publication Critical patent/CR20240342A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CR20240342A 2022-01-13 2023-01-12 Vegf y proteína de fusión de unión a tie2 y sus usos descripción CR20240342A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263299177P 2022-01-13 2022-01-13
US202263310359P 2022-02-15 2022-02-15
US202263335805P 2022-04-28 2022-04-28
PCT/US2023/060582 WO2023137395A1 (en) 2022-01-13 2023-01-12 Vegf and tie2-binding fusion protein and uses thereof

Publications (1)

Publication Number Publication Date
CR20240342A true CR20240342A (es) 2024-09-18

Family

ID=87279731

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20240342A CR20240342A (es) 2022-01-13 2023-01-12 Vegf y proteína de fusión de unión a tie2 y sus usos descripción

Country Status (16)

Country Link
US (1) US20230287109A1 (cg-RX-API-DMAC7.html)
EP (1) EP4463482A4 (cg-RX-API-DMAC7.html)
JP (1) JP7884072B2 (cg-RX-API-DMAC7.html)
KR (1) KR20250005053A (cg-RX-API-DMAC7.html)
AU (1) AU2023206363A1 (cg-RX-API-DMAC7.html)
CA (1) CA3242904A1 (cg-RX-API-DMAC7.html)
CL (2) CL2024002106A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024010934A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240342A (cg-RX-API-DMAC7.html)
DO (1) DOP2024000136A (cg-RX-API-DMAC7.html)
GE (1) GEAP202416581A (cg-RX-API-DMAC7.html)
IL (1) IL314219A (cg-RX-API-DMAC7.html)
JO (1) JOP20240158A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024008737A (cg-RX-API-DMAC7.html)
PE (1) PE20260003A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023137395A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250128899A (ko) * 2024-02-20 2025-08-28 주식회사 맵틱스 Tie2 및 VEGF에 특이적으로 결합하는 이중 특이적 항체 및 이의 용도
WO2026036282A1 (en) * 2024-08-13 2026-02-19 Pentavision Biosciences Limited Multispecific fusion proteins targeting angiogenic factors
US20260226178A1 (en) * 2024-12-23 2026-08-06 Ingenia Therapeutics, Inc. Fusion Proteins Comprising a Tie2 Binding Domain

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3415533A1 (en) * 2011-08-19 2018-12-19 Regeneron Pharmaceuticals, Inc. Anti-tie2 antibodies uses thereof
JP2020501508A (ja) * 2016-09-15 2020-01-23 クアドルセプト バイオ リミテッド 多量体、四量体および八量体
JP2021507723A (ja) * 2017-12-05 2021-02-25 ユニバーシティ オブ ワシントンUniversity of Washington 視細胞における治療遺伝子の機能的発現を増強するための組成物および方法
WO2019235856A1 (ko) * 2018-06-07 2019-12-12 기초과학연구원 Tie2에 결합하는 항체 및 이의 용도
EP3805265A4 (en) * 2018-06-07 2022-07-06 Institute for Basic Science ANTIBODIES BINDING TO TIE2 AND USES THEREOF
JP2021529557A (ja) * 2018-06-29 2021-11-04 ジェンサン バイオファーマ、 インコーポレイテッドGensun Biopharma, Inc. 抗腫瘍免疫チェックポイント調節因子アンタゴニスト
JP7249060B2 (ja) * 2018-08-17 2023-03-30 トリカン・バイオテクノロジー・カンパニー・リミテッド 抗血管新生融合タンパク質およびその使用
EP3856245A4 (en) 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES AGAINST HPTP - BETA (VE-PTP) AND VEGF
AU2020385991A1 (en) * 2019-11-21 2022-06-23 Unity Biotechnology Antibodies directed to Tie-2 and methods of use
CA3169967A1 (en) * 2020-03-24 2021-09-30 Genentech, Inc. Tie2-binding agents and methods of use

Also Published As

Publication number Publication date
IL314219A (en) 2024-09-01
KR20250005053A (ko) 2025-01-09
GEAP202416581A (en) 2024-12-10
JP7884072B2 (ja) 2026-07-02
WO2023137395A1 (en) 2023-07-20
DOP2024000136A (es) 2024-10-15
AU2023206363A1 (en) 2024-08-15
CL2025002473A1 (es) 2025-11-14
MX2024008737A (es) 2024-09-11
US20230287109A1 (en) 2023-09-14
JOP20240158A1 (ar) 2024-07-14
CA3242904A1 (en) 2025-03-14
JP2025503704A (ja) 2025-02-04
EP4463482A1 (en) 2024-11-20
CL2024002106A1 (es) 2025-03-28
EP4463482A4 (en) 2026-05-06
PE20260003A1 (es) 2026-01-06
CO2024010934A2 (es) 2024-10-31

Similar Documents

Publication Publication Date Title
MX2024008737A (es) Vegf y proteina de fusion de union a tie2 y sus usos.
CO6270370A2 (es) Inhibicion de angiogenesis mediante antagonistas o anticuerpos bv8
ECSP20014523A (es) Conjugado de anticuerpo monoclonal contra bcma-fármaco
PE20200011A1 (es) ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
PE20210045A1 (es) Anticuerpos agonistas contra pd-1 y usos de estos
MX2021004045A (es) Metodos para tratar cancer con una combinacion de un anticuerpo anti factor de crecimiento endotelial vascular (vegf) y un conjugado de anticuerpo anti factor tisular-farmaco.
PE20191758A1 (es) Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares
PE20091029A1 (es) Anticuerpos anti-alfa 5 beta 1
MX2022005850A (es) Inmunoglobulinas modificadas para seleccionar depositos de amiloide como objetivo.
EP4509143A3 (en) Cd38 antibody drug conjugate
WO2019168947A8 (en) Bifunctional proteins combining checkpoint blockade for targeted therapy
BR112017025080A2 (pt) composto conjugado de fármaco com anticorpo anti-cd123, composição conjugada de fármaco com anticorpo, método de tratamento de um paciente que tem um câncer que expressa cd123, composição farmacêutica, e, anticorpo intacto ou fragmento de ligação de antígeno
JOP20240198A1 (ar) أنظمة مضادة لـ vegf ممتدة عالية الجرعة لعلاج اضطرابات وعائية المنشأ بالعين
BR112023016574A2 (pt) Composições de anticorpo anti-tl1a e métodos de tratamento no pulmão
PE20220487A1 (es) Anticuerpos anti-ms4a4a y metodos de uso de los mismos
MX2020007406A (es) Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo.
MX2022002366A (es) Tratamiento de la retinopatía diabética con fab anti-vegf completamente humano modificado postraduccionalmente.
PH12023550032A1 (en) Tubulysins and protein-tubulysin conjugates
MY208067A (en) Tubulysins and protein-tubulysin conjugates
MX2022003668A (es) Metodos y composiciones para el tratamiento de la retinopatia diabetica.
WO2019030762A3 (en) CANNABIS AND ITS DERIVATIVES FOR THE TREATMENT OF PAIN RELATED TO PAIN AND BONE REGENERATION ASSOCIATED WITH BONE DEFECTS IN THE JAW
MX2022015959A (es) Anticuerpo anti-fxi/fxia, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.
AR124914A1 (es) Nuevo anticuerpo anti-pad4
SA520420225B1 (ar) cMET مترافقات عقار من عوامل رابطة أحادية النسيلة من واستخداماتها
PH12022552725A1 (en) Anti-ox40 antibody and uses thereof